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Early calcification of a Carpentier-Edwards Perimount mitral valve in an
elderly woman
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In mitral valve surgery, the valve is replaced when repair isnot feasible. Mechanical or biologic prostheses are the op-tions. Mechanical valves have extended durability but re-quire life-long anticoagulation. Bioprostheses do not require
anticoagulant therapy, but they have a limited life because of
structural valve deterioration, necessitating reoperation.
Carpentier-Edwards Perimount (CEP) bioprostheses (Baxter
Healthcare Corporation CardioVascular Group, Irvine, Calif) are a
reliable choice for valve replacement, especially in elderly pa-
tients, because they avoid the need for anticoagulation and its
associated morbidity. Recent studies in long-term follow-up show
low rates of structural valve deterioration among patients older
than 60 years at implantation. We report here early mitral biopros-
thesis calcification in an elderly woman that produced clinical
symptoms of valve stenosis, necessitating reoperation.
Clinical Summary
A 75-year-old woman with history of arterial hypertension, hyper-
cholesterolemia, and chronic atrial fibrillation, in New York Heart
Association functional class III, underwent mitral valve replace-
ment for mitral stenosis. Preoperative echocardiography and cath-
eterization confirmed valvulopathy, showed good contractile func-
tion of the left ventricle, and revealed normal coronary arteries.
The native valve was excised and replaced with a 29-mm CEP
pericardial bioprosthesis. The patient made an uneventful recovery
and was discharged on the fifth postoperative day.
After the valve replacement, the patient’s functional class im-
proved. One year later, she was operated on to resect an epider-
moid neoplasm in the tongue but otherwise appeared to be in good
health. However, 45 months later she reported fatigue, dyspnea
with rest, and orthopnea. Physical examination discovered a new
cardiac murmur at the apex. Echocardiography and cardiac cath-
eterization revealed a calcified prosthetic stenosis with median
transvalvular gradient of 31 mm Hg, an estimated valve area of 0.9
cm2, and severe pulmonary hypertension (pulmonary artery sys-
tolic pressure 78 mm Hg, pulmonary capillary wedge pressure 52
mm Hg). Hyperparathyroidism was eliminated as a cause of bio-
prosthesis calcification, because the patient’s calcium (9 mg/dL
[normal values 8.8-10.5 mg/dL]) and phosphate (4.3 mg/dL [nor-
mal values 2.5-4.9 mg/dL]) blood levels were normal, and there
were no calcium deposits at other organ sites.
The patient was accepted for repeated mitral valve surgery. At
operation, the CEP valve leaflets were found to be rigid and
completely infiltrated by calcium, with limited opening movement
(Figures 1 and 2). The bioprosthesis was explanted and replaced
with a 27-mm St Jude Medical mechanical valve (St Jude Medical
Inc, Minneapolis, Minn). The patient made an uneventful recovery
from this second operation.
Discussion
Structural deterioration is the principal complication of biologic
valves and the main cause of reoperation. Structural valve deteri-
oration is defined as any change in valve function resulting from an
intrinsic abnormality causing stenosis or regurgitation (it excludes
infected or thrombosed valves as determined on explantation and
includes changes intrinsic to the valve, such as wear, calcification,
leaflet tear, and stent creep).1 Pericardial valves, like porcine ones,
are vulnerable to two types of structural failure: leaflet tearing and
calcification.2 Early calcification of bioprostheses has been de-
scribed in the younger age group, in patients taking calcium
supplements or with calcium metabolism disorders, and in differ-
ent types of bioprostheses (pericardial valves are less prone to
calcification than are porcine valves). Calcium deposits are asso-
ciated with the adsorption of proteins and phospholipids and with
platelet deposition.3
CEP valve leaflets are bovine pericardium, fixed without pres-
sure in glutaraldehyde and designed by computer-generated leaflet
sizing according to stent size so that commissural stress is mini-
mal. The tissue of these prostheses is treated with the surfactant
polysorbate 80, an antimineralization agent that reduces calcifica-
tion by extraction of phospholipids from the valve tissue.
Marchand and associates,4 in their long-term evaluation study
of these prostheses at 15 years, recommended the use of the CEP
because it seems to be free of structural failure caused by leaflet
tearing and has low levels of structural valve deterioration from
calcification in patients older than 60 years. In patients older than
70 years the results seem excellent, with 100% both actual and
actuarial freedoms from explantation for structural valve deterio-
ration.
Early failure of a bioprosthesis from calcification is exceptional
in elderly patients.5 We did not find in the literature any other cases
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of early calcification affecting the CEP bioprosthesis in an elderly
patient. Our patient had normal calcium and phosphate levels, and
we did not find calcifications affecting other organs (eg, bone and
kidney), so hyperparathyroidism was excluded as the cause of
prosthesis calcification.
After this experience and after reviewing the studies about
long-term follow-up with the CEP valve, we still think that this
prosthesis could be the first choice for valve replacement in an
elderly patient. Although it is a rare complication, however, valve
failure from calcification can appear at any time after implantation
in any patient, even the oldest. Periodically clinical follow-up and
serial echocardiography will permit a prompt detection of struc-
tural valve deterioration and allow suitable treatment in individual
cases.
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Figure 1. Carpentier-Edwards Perimount valve explanted. It was
rigid, heavily calcified, with minimal open movement of the 3
cusps.
Figure 2. X-ray analysis of the bioprosthesis explanted. Extensive
calcium deposits are evident in the cusps.
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